Nicotinamide adenine dinucleotide

Investigated uses

• Infusion pharmacokinetics; wellness, addiction, energy and cognition claims remain unproven.

Mechanism and hypotheses

• NAD+ is an essential redox coenzyme; a small uncontrolled infusion study characterized plasma and urinary metabolites.
• Hypothesized: Energy, cognition, addiction or longevity benefits from intravenous NAD+ have not been established by that pharmacokinetic study.

Human evidence

• A small open-label infusion study described NAD+ and metabolite kinetics during a six-hour infusion. Limitations: No control group and no validated clinical-efficacy endpoint.

Safety highlights

• The small infusion study was not designed to define a population adverse-event rate.
• Rapid infusion, contamination, electrolyte/pH variation and unknown excipients are formulation-specific concerns.

Regulatory context

No FDA-approved product matching the exact catalog presentation was identified in this review.